Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals

globenewswire.com
RPTX Replimune's vusolimogene oderparepvec in melanoma is mentioned as a catalyst event with an expected approval decision in Q2 2026. The article does not provide specific sentiment on the outcome. ARVN Arvinas's vepdegestrant in ER+/HER2-Negative Breast Cancer is listed as a catalyst event with an expected approval decision in Q2 2026. The article does not offer a specific sentiment regarding the approval. RGNX Regenxbio's Phase III trial results in Duchenne muscular dystrophy are discussed as an ongoing clinical trial. The article does not provide sentiment on the expected results.

Catalyst Monitor: Q2 2026 Outlook Report - Trial Initiations, Completions, Top-line Results, Regulatory Filings, PDUFA Dates, and Expected Approvals Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q2 2026 Outlook" report has been added to ResearchAndMarkets.com's offering.

This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q2 2026.

The latest report, "Catalyst Monitor Q2 2026", delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 15 significant catalyst events that are expected to occur in Q2 2026.

Some of the catalysts covered in the report, include approval decisions for Replimune's vusolimogene oderparepvec in melanoma, Arvinas's vepdegestrant in ER+/HER2-Negative Breast Cancer, and more.

Additionally, experts also discuss expectations about the ongoing clinical trials such as Regenxbio's Phase III trial results in Duchenne muscular dystrophy and Boehringer Ingelheim's Phase III trial results in obesity, and more.

The Catalyst Monitor report is published on a quarterly basis. The data presented in this report reflects the database as of 26 March.

Report Scope

This Report Will Enable the User to Answer the Following Questions:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/v6c1d5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.